Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Payables (2023 - 2025)

Historic Payables for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $786000.0.

  • Contineum Therapeutics' Payables fell 4373.66% to $786000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $786000.0, marking a year-over-year decrease of 4373.66%. This contributed to the annual value of $1.8 million for FY2024, which is 18519.69% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Payables of $786000.0 as of Q3 2025, which was down 4373.66% from $2.0 million recorded in Q2 2025.
  • Contineum Therapeutics' Payables' 5-year high stood at $3.6 million during Q1 2025, with a 5-year trough of $570000.0 in Q1 2024.
  • For the 3-year period, Contineum Therapeutics' Payables averaged around $1.4 million, with its median value being $1.1 million (2024).
  • Data for Contineum Therapeutics' Payables shows a peak YoY increase of 53947.37% (in 2025) and a maximum YoY decrease of 4373.66% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Payables stood at $635000.0 in 2023, then skyrocketed by 185.2% to $1.8 million in 2024, then plummeted by 56.6% to $786000.0 in 2025.
  • Its Payables stands at $786000.0 for Q3 2025, versus $2.0 million for Q2 2025 and $3.6 million for Q1 2025.